{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:41:47Z","timestamp":1787510507132,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40265-024-02073-w","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T03:46:41Z","timestamp":1722224801000},"page":"1135-1142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Ivonescimab: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"issue":"4","key":"2073_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):339\u201357.","journal-title":"Ann Oncol"},{"key":"2073_CR2","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology: non small cell lung cancer (version 7.2024). 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed 10 July 2024."},{"key":"2073_CR3","unstructured":"PR Newswire. Ivonescimab in combination with chemotherapy approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A clinical trial: positive trend observed in overall survival towards ivonescimab plus chemotherapy [media release]. 1 June 2024. https:\/\/www.prnewswire.com\/news-releases\/ivonescimab-in-combination-with-chemotherapy-approved-in-china-by-nmpa-for-2l-egfrm-nsclc-based-on-harmoni-a-clinical-trial-positive-trend-observed-in-overall-survival-towards-ivonescimab-plus-chemotherapy-302161109.html."},{"key":"2073_CR4","unstructured":"Akeso Biopharma. Ivonescimab (\u4f9d\u8fbe\u65b9): Chinese prescribing information. Zhongshan City: Kangfang Sino Pharmaceutical Co; 2024."},{"key":"2073_CR5","unstructured":"Akeso Biopharma. Akeso Inc. announces collaboration and license agreement for up to US$5 billion with Summit Therapeutics to accelerate global development and commercialization of its breakthrough bispecific antibody, ivonescimab (PD-1\/VEGF) [media release]. 6 Dec 2022. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/20221206\/."},{"key":"2073_CR6","unstructured":"Summit T. Summit Therapeutics closes deal with Akeso Inc. to in-license breakthrough innovative bispecific antibody [media release]. 20 Jan 2023. https:\/\/www.smmttx.com\/pressrelease\/summit-therapeutics-closes-deal-with-akeso-inc-to-in-license-breakthrough-innovative-bispecific-antibody\/."},{"key":"2073_CR7","unstructured":"Summit Therapeutics. Summit raises $200 million; also expands license territories for ivonescimab [media release]. 3 June 2024. https:\/\/www.smmttx.com\/pressrelease\/summit-raises-200-million-also-expands-license-territories-for-ivonescimab\/."},{"key":"2073_CR8","doi-asserted-by":"crossref","unstructured":"Zhong TT, Huang ZL, Pang XH, et al. AK112, a tetravalent bispecific antibody targeting PD-1 and VEGF, enhances binding avidity and functional activities and elicits potent anti-tumor efficacy in pre-clinical studies [abstract no. 521 plus poster]. J Immunother Cancer. 2022;10(Suppl 2):A546\u20137.","DOI":"10.1136\/jitc-2022-SITC2022.0521"},{"key":"2073_CR9","doi-asserted-by":"crossref","unstructured":"Zhong TT, Huang ZL, Pang XH, et al. Mechanism of action of ivonescimab (AK112\/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects [abstract no. B123 plus poster]. Mol Cancer Ther. 2023;22(12_Suppl).","DOI":"10.1158\/1535-7163.TARG-23-B123"},{"key":"2073_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10613","author":"W Fang","year":"2024","unstructured":"Fang W, Zhao Y, Luo Y, et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA. 2024. https:\/\/doi.org\/10.1001\/jama.2024.10613.","journal-title":"JAMA"},{"key":"2073_CR11","doi-asserted-by":"crossref","unstructured":"Zhang L, Fang W, Zhao Y, et al. Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): a randomized, double-blind, multi-center, phase 3 trial [abstract no. 8508 plus oral presentation]. J Clin Oncol. 2024;42(16_suppl).","DOI":"10.1200\/JCO.2024.42.16_suppl.8508"},{"key":"2073_CR12","unstructured":"Summit Therapeutics. Ivonescimab monotherapy decisively beats pembrolizumab monotherapy head-to-head, achieves statistically significant superiority in PFS in first-line treatment of patients with PD-L1 positive NSCLC in China [media release]. 30 May 2024. https:\/\/www.smmttx.com\/pressrelease\/ivonescimab-monotherapy-decisively-beats-pembrolizumab-monotherapy-head-to-head-achieves-statistically-significant-superiority-in-pfs-in-first-line-treatment-of-patients-with-pd-l1-positive-nsclc-in\/."},{"key":"2073_CR13","unstructured":"US National Institutes of Health. ClinicalTrials identifier NCT05499390. 2022. https:\/\/clinicaltrials.gov\/study\/NCT05499390. Accessed 11 July 2024."},{"key":"2073_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Chen G, Chen J, et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine. 2023;62: 102106.","journal-title":"EClinicalMedicine."},{"key":"2073_CR15","doi-asserted-by":"crossref","unstructured":"Zhang L, Fang WF, Zhao Y, et al. Phase II results of ivonescimab (ivo) a novel PD-1\/VEGF bispecific in combination with chemotherapy for first-line treatment of patients (pts) with advanced\/metastatic squamous (sq) non-small cell lung cancer (NSCLC) [abstract no. 68P plus poster]. ESMO Open. 2024;9(Suppl 3):36.","DOI":"10.1016\/j.esmoop.2024.102647"},{"issue":"3","key":"2073_CR16","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jtho.2023.10.014","volume":"19","author":"L Wang","year":"2024","unstructured":"Wang L, Luo Y, Ren S, et al. A phase 1b study of ivonescimab, a programmed cell death protein-1 and vascular endothelial growth factor bispecific antibody, as first- or second-line therapy for advanced or metastatic immunotherapy-naive NSCLC. J Thorac Oncol. 2024;19(3):465\u201375.","journal-title":"J Thorac Oncol"},{"key":"2073_CR17","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhou C, Fang WF, et al. Intracranial (IC) activity of ivonescimab (ivo) alone or in combination with platinum doublet chemotherapy (PC) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and brain metastases (BMs) [abstract no. 174P plus poster]. ESMO Open. 2024;9(S3):3\u20134.","DOI":"10.1016\/j.esmoop.2024.102749"},{"issue":"4","key":"2073_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008037","volume":"12","author":"S Frentzas","year":"2024","unstructured":"Frentzas S, Austria Mislang AR, Lemech C, et al. Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors. J Immunother Cancer. 2024;12(4): e008037.","journal-title":"J Immunother Cancer"},{"key":"2073_CR19","doi-asserted-by":"crossref","unstructured":"Yung J, Xie Y, Xu Q, et al. The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer [abstract no. 4095 plus poster]. J Clin Oncol. 2024;42(16_suppl).","DOI":"10.1200\/JCO.2024.42.16_suppl.4095"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02073-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T04:32:22Z","timestamp":1727497942000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02073-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["2073"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02073-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"11 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}